FDA: Boxed Warning for Promethazine Hydrochloride Injection

Sep 16th of 2009

Drugs Immunology ADD and ADHD

The U.S. Food and Drug Administration is telling manufacturers of the drug promethazine to include a boxed warning regarding the injectable form of the drug. The warning, under FDA's authority to require safety labeling changes, will highlight the risk of serious tissue injury when this drug is administered incorrectly. The agency is also alerting health care professionals to the new boxed warning for this product, which is used as a sedative and to treat nausea and vomiting.

ADHD Medication Treatment Associated with Higher Academic Performance in Elementary School

Apr 20th of 2009

General ADD and ADHD

Children with attention deficit hyperactivity disorder (ADHD) who take medication to treat the condition tend to do better in math and reading compared to their peers who also have ADHD but do not take medication, according to data from a national survey. The NIMH-funded study was published in the May 2009 issue of Pediatrics.

Short-term Intensive Treatment Not Likely to Improve Long-term Outcomes for Children with ADHD

Mar 27th of 2009

General ADD and ADHD

Initial positive results gleaned from intensive treatment of childhood attention deficit hyperactivity disorder (ADHD) are unlikely to be sustained over the long term, according to a recent analysis of data from the NIMH-funded Multimodal Treatment Study of Children with ADHD (MTA). The study was published online ahead of print March 2009 in the Journal of the American Academy of Child and Adolescent Psychiatry.

Long-term Academic Effects of Child?s ADHD May Extend to Siblings

Dec 3rd of 2008

General ADD and ADHD

The long-term academic problems that children with attention deficit hyperactivity disorder (ADHD) often experience may affect their siblings as well, according to an analysis partially funded by NIMH and published in the Journal of Health Economics.